drug · protein
motixafortide acetate
Marketedupdated 6mo agoby $BLRX BioLineRx Ltd.🔗 ChEMBL
Approvedcommunity read0 votes
🐶 often sniffed alongside
top 1Protein drug with a maximum clinical stage of Approval (across all indications), with an approval for multiple myeloma and 1 investigational indication.
all catalysts(0)
nothing on the calendar yet
Patent cliff
source: FDA Orange Bookfirst barrier falls
Sep 8, 2028
~1.8 years out
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (2)
- Dec 29, 2041formulationUS 12257285
- Dec 29, 2041formulationUS 12268725
FDA exclusivities (2)
- Sep 8, 2030ODE-442Orphan Drug (7y)3.8y
- Sep 8, 2028NCENew Chemical Entity (5y)1.8y
News(2)
- Karyopharm files for bankruptcy, looks to merger with Ayrmid for life raftDebtor-in-process financing up to $55 million could keep the lights on at Karyopharm Therapeutics for its multiple myeloma and myelofibrosis programs as the biotech waits to see if its union with A…biospace · 11d ago
- Karyopharm files Chapter 11, lines up Ayrmid as lead bidder in planned mergerIn an answer to Karyopharm's cash crisis, Irish biotech Ayrmid has agreed to make the first bid on the struggling biopharma's assets in a court supervised auction, teeing up a potential hematology…fiercebiotech · 11d ago
Data sources
last refreshed 4h ago
Found something off?
comments(0)
5-min edit window · permanent after that